Aldevron

Executive Summary

Aldevron is a premier contract development and manufacturing organization (CDMO) that supplies high-quality biological materials—including plasmid DNA, proteins, enzymes, antibodies, and RNA—to the life sciences industry. Founded in 1998 and headquartered in Fargo, North Dakota, the company supports partners from research through clinical trials and commercialization, playing a critical role in the genomic medicine supply chain. With increasing demand for gene therapies and mRNA-based treatments, Aldevron is well-positioned to capitalize on its established manufacturing expertise and reputation for quality. As a private company, financial details are limited, but its strategic importance in the biotech ecosystem suggests strong growth potential.

Upcoming Catalysts (preview)

• Q3 2026Expansion of plasmid DNA manufacturing capacity to meet growing gene therapy demand80% success
• Q1 2027New strategic partnership or multi-year supply agreement with a top-20 biopharma company60% success
• TBDPotential acquisition by a larger CDMO seeking to strengthen its nucleic acid capabilities40% success